文献速递血管炎其他结缔组织病自身炎症与 IgG4 相关病

从主动脉炎到Sweet综合征:G-CSF不良事件的免疫谱

From Aortitis to Sweet's: The Immune Spectrum of G-CSF Adverse Events.
PubMed 文献 · Semin Arthritis Rheum · 2026-02-02

血管事件多在pegfilgrastim后7-15天出现,非血管事件在2-7天出现;管理包括停药、短期糖皮质激素、换用短效filgrastim及IL-6阻断。

要点

  • pegfilgrastim相关主动脉炎潜伏期7-15天,非血管事件2-7天。
  • 急性期反应物显著升高,自身抗体通常阴性,停药后多好转。
  • CPPD复发可换用短效filgrastim,难治性主动脉炎可用IL-6阻断。

核心结论

  • 外源性G-CSF可触发一组免疫介导毒性,具有表型特异的时间窗和管理策略。

主要发现

  • 队列量化了pegfilgrastim相关主动脉炎的较低但可重复的负担,典型累及主动脉弓/近端分支,潜伏期7-15天。
  • 病例数据证实急性期反应物显著升高,自身抗体通常阴性,停药后伴或不伴短期糖皮质激素多预后良好,再暴露可复发/迁移。
  • 非血管事件更早出现(2-7天),包括活检证实的Sweet综合征/NDDH、白细胞碎裂性血管炎、CPPD复发和罕见弥漫性肺泡出血。

关键数值与推荐

  • 血管事件潜伏期7-15天,非血管事件2-7天。
  • 再暴露信息提示表型特异性风险:pegfilgrastim相关CPPD复发可通过换用短效filgrastim减轻。
  • 部分局限性主动脉炎未用激素即缓解,难治性主动脉炎对IL-6阻断有反应。

临床怎么用

  • 识别依赖时间关联、影像/组织学及排除模拟者。
  • 管理为表型感知:停药±短期糖皮质激素,CPPD换用制剂,难治性主动脉炎靶向IL-6阻断。

局限性

  • 证据主要来自病例报告和短系列,观察性队列仅2项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Granulocyte colony-stimulating factor (G-CSF) and its PEGylated formulation (pegfilgrastim) are indispensable for preventing chemotherapy-induced neutropenia and for stem-cell mobilization. Beyond hematopoiesis, G-CSF modulates innate/adaptive immunity and may precipitate immune-mediated events in susceptible hosts. Clinical signals span large-vessel vasculitis/aortitis and non-vascular neutrophil-dominant phenotypes, yet timing, spectrum, and management remain variably characterized. OBJECTIVE: To identify and synthesize primary clinical reports of autoimmune/rheumatic disease triggered or exacerbated by exogenous G-CSF (filgrastim or pegfilgrastim), describing phenotypes, latency, management, outcomes, and implications for practice. METHODS: We performed a narrative review of primary clinical studies, including observational cohorts and case reports or short case series, identified through targeted searches of PubMed/MEDLINE, Scopus, and Embase, complemented by investigator-curated references. Eligible reports described autoimmune, inflammatory, or rheumatic manifestations occurring after exposure to exogenous G-CSF. Predefined phenotypes included large-vessel vasculitis/aortitis; neutrophilic dermatoses (e.g., Sweet's syndrome, neutrophilic dermatosis of the dorsal hands); cutaneous small-vessel vasculitis; inflammatory or crystal arthritis (e.g., calcium pyrophosphate deposition disease); pulmonary inflammatory injury (e.g., diffuse alveolar hemorrhage); and clear flares of established autoimmune disease. Narrative or mechanistic reviews and trials of GM-CSF pathway blockade were excluded from qualitative synthesis. RESULTS: Twenty-four studies met inclusion criteria: two observational cohorts and twenty-two single-patient reports/short series. Cohorts quantified a low but reproducible burden of pegfilgrastim-associated aortitis, with stereotyped involvement of the aortic arch/proximal branches and typical latency of 7-15 days. Case-level data confirmed marked elevation of acute phase reactants, usually negative autoantibodies, favorable outcomes after G-CSF withdrawal with or without short glucocorticoid courses, and recurrence/migration on re-exposure. Non-vascular events clustered earlier (2-7 days) and included biopsy-proven Sweet's/NDDH, leukocytoclastic vasculitis, CPPD flares, and rare diffuse alveolar hemorrhage; granulomatous dermatitis and perioperative pyoderma gangrenosum were also observed. Re-exposure information suggested phenotype-specific risk: recurrent CPPD with pegfilgrastim was mitigated by switching to short-acting filgrastim; selected limited aortitis resolved without steroids; refractory aortitis responded to IL-6 blockade, enabling uninterrupted chemotherapy. CONCLUSIONS: Exogenous G-CSF can precipitate a coherent spectrum of immune-mediated toxicity with distinct, clinically actionable timing windows: vascular events peak 7-15 days after pegfilgrastim, whereas cutaneous, articular, and pulmonary manifestations arise within 2-7 days. Recognition hinges on temporal linkage, imaging/histology, and exclusion of mimics. Management is phenotype-aware-drug withdrawal ± short glucocorticoids, formulation switching for CPPD, and targeted IL-6 blockade in selected refractory aortitis-allowing preservation of hematologic benefits while minimizing immune toxicity. Prospective surveillance and structured re-exposure studies (including formulation tailoring) are priorities to move from signal detection to prevention.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. de Carvalho JF, Caldas CAM. From Aortitis to Sweet's: The Immune Spectrum of G-CSF Adverse Events. Semin Arthritis Rheum. 2026. PMID: 41655516. doi:10.1016/j.semarthrit.2026.152939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。